Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

20.88 +4.37 (+26.47%)
Official Closing Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Israeli-Hamas War: U.S. Exchange-Listed Israeli Stocks Continue To Decline
The 111 Israeli companies with stocks trading on US exchanges have combined market caps over $150B. Or at least they did midweek: since the Hamas-Israeli War began October 7th, pretty much everything... 
Via Talk Markets
Investor Exit Israel ETFs Following Attacks, But Remain Confident In Large-Caps
Israel-focused ETFs have plunged since the last trading day before Hamas launched surprise attacks on Israel, while some Israeli companies listed in the U.S. have so far escaped repercussions to their... 
Via Benzinga
Topics ETFs
Thoughts For Thursday: War Worries Rattle The Market
Via Talk Markets
Hamas-Israeli War: US Exchange Listed Israeli Stocks Hit Hard
111 Israeli companies trade on U.S. stock exchanges of which only 15 have market capitalization of $2B or more. 
Via Talk Markets
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
From Teva Pharmaceutical Industries Limited
Via Business Wire
Israel Could Form Emergency Government: Defense Stocks, Israel ETFs In Focus During Conflict
As Israel ramps up its armed forces and a regional war with Hamas enters its fourth day, the country is considering forming an emergency government. 
Via Benzinga
Topics ETFs
Israeli Stocks Fall as Investors Fear Middle East Conflict
The recent attacks on Israel will have a lasting economic impact. Here's what investors should know about Israeli stocks. 
Via InvestorPlace
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil. 
Via Benzinga
Topics ETFs
Why Teva Pharmaceutical (TEVA) Stock Is Falling
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are trading lower by 2.7% to $9.17 Monday morning amid conflict in the company's home country, Israel. 
Via Benzinga
Middle East War Hammers Israel-Based Stocks But Lifts Defense, Oil Names
Israel stocks, regardless of industry, sank Monday following the terrorist attack on Israel. 
Via Investor's Business Daily
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and  
Via Benzinga
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Migraine Medication Battle: Eli Lilly Prevails in Patent Infringement Case Against Teva
A federal judge in Massachusetts has overturned a $176.5 million jury verdict against Eli Lilly And Co (NYSE: LLY). T 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to... 
Via Benzinga
3 No-Brainer Stocks to Buy With $20 Right Now
You don't need a boatload of cash to begin growing your wealth on Wall Street. 
Via The Motley Fool
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
Last year, Teva Pharmaceutical Industries Ltd (NYSE: TEVA), the primary producer of Adderall, faced shortages  
Via Benzinga
TEVA - A Pharma Stock To Watch
TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high. The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How A Small Indian Firm Firm Was Pulled Into A Legal Battle with Big Pharma Over A Cancer Drug
This story was first published on the Benzinga India portal. 
Via Benzinga
Bristol Myers' Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.